SRRK: ISEMBYLD receives FDA approval as the first muscle-targeted SMA therapy, launching in the U.S

FDA approved ISEMBYLD as the first muscle-targeted therapy for SMA in patients aged 2 and older on SMN2-targeted treatment, based on robust Phase 3 data showing significant motor function improvement. U.S. launch is underway, with support services and broad access initiatives in place.Original docu…